Skip to main content
Premium Trial:

Request an Annual Quote

Lumera's Q2 Revenues Rise 40 Percent on Govt. Contracts

NEW YORK (GenomeWeb News) — Lumera yesterday said second-quarter revenues grew 40 percent as R&D spending fell 13 percent and net loss grew 3 percent.
Total receipts for the three months ended June 30 increased to $934,000 from $665,000 year over year.
Nearly all of the company’s revenue came from US government service contracts, Lumera said. Much of the gain in revenue was due to a contract with the Defense Advanced Research Projects Agency to develop electro-optic polymer modulators. Electro-optic product sales contributed $6,000 over the quarter.
Lumera did not break out revenues for its bioscience business, which it recently restructured into a wholly owned subsidiary called Plexera Biosciences.
R&D spending dipped to $1.4 million from $1.6 million in the year-ago period.
Lumera said net loss rose to $3.3 million from $3.2 million in the year-ago period. 
Lumera said it had around $2.9 million in cash and cash equivalents as of June 30.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.